Alphaeon is a technology company.
Alphaeon has raised $107.0M across 2 funding rounds.
Alphaeon has raised $107.0M in total across 2 funding rounds.
Alphaeon has raised $107.0M in total across 2 funding rounds.
Alphaeon's investors include Longitude Capital.
Alphaeon Corporation is a healthcare technology company that provides financing solutions, primarily through its Alphaeon Credit platform, to patients seeking elective procedures in self-pay segments like plastic surgery, ophthalmology, dentistry, and dermatology.[1][2][3] It serves healthcare providers by offering user-friendly credit options with high approval rates, superior credit limits, and quick application processes (under 5 minutes), enabling practices to help more patients afford treatments without impacting credit scores initially.[1][3] As a subsidiary of private equity firm Strathspey Crown LLC, Alphaeon focuses on bridging financial gaps in aesthetic and medical care, with reported revenue around $36 million and total funding of $107.4 million across five rounds.[2]
Alphaeon Corporation was founded in July 2013 by Robert E. Grant, its former CEO, as a wholly owned subsidiary of Strathspey Crown LLC, a Newport Beach-based private equity firm.[1] Headquartered initially in Irvine, California (with some sources noting Newport Beach), the company emerged to address financing needs in elective healthcare, targeting self-pay markets underserved by traditional lending.[1][2] A pivotal moment came in January 2020, when Alphaeon reorganized into two units: AEON Biopharma, Inc. (focused on biopharma) and Alphaeon1 LLC (operating as Alphaeon Credit for financing).[1] This split sharpened its focus on credit services, building early traction through provider partnerships that praised its simplicity and customer service.[3]
Alphaeon rides the wave of fintech-healthcare convergence, capitalizing on rising demand for elective, cash-pay procedures amid growing consumer spending on aesthetics and wellness—segments projected to expand with aging populations and social media-driven beauty standards.[1][2] Its timing aligns with post-2020 shifts toward specialized financing as traditional insurance lags in covering cosmetics and electives, while market forces like high patient out-of-pocket costs (exacerbated by inflation) favor accessible credit solutions.[3] By empowering thousands of practices, Alphaeon influences the ecosystem through higher procedure volumes, fostering innovation in provider-patient financial tools and indirectly supporting medtech growth in underserved specialties.[1][3]
Alphaeon is poised to expand its credit platform amid booming elective healthcare demand, potentially integrating AI-driven approvals or partnerships with telehealth for broader reach. Trends like personalized medicine financing and rising self-pay volumes (fueled by wellness booms) will shape its path, with its provider-first model driving adoption. Its influence may evolve from niche financier to ecosystem enabler, especially if it scales beyond current segments—building on its reorganization momentum to capture more of the $50B+ U.S. aesthetics market. This positions Alphaeon as a quiet powerhouse in healthcare fintech, much like its origins in solving real provider pain points.
Alphaeon has raised $107.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in November 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2015 | $80.0M Series B | Longitude Capital | |
| Jan 1, 2015 | $27.0M Series A | Longitude Capital |